Some price data may be temporarily unavailable.
The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
Myovant Sciences is a biotech company that develops new treatments for infertility in women and prostate cancer in men. The company's product capabilities and help continue to deliver innovative therapies addressing unmet patient needs in prostate cancer and women’s health. Myovant Sciences was established in 2016 and is based in Brisbane, California.
Myovant said "no thanks" to an acquisition offer in hopes to fetch a higher price.
The FDA has identified deficiencies with Myovant's regulatory filing for Myfembree.
MYOV earnings call for the period ending June 30, 2022.
MYOV earnings call for the period ending March 31, 2022.
MYOV earnings call for the period ending December 31, 2021.
MYOV earnings call for the period ending September 30, 2021.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.